publication date: Apr. 18, 2016

Sosman Named Director of Melanoma Program at Northwestern University 


JEFFREY SOSMAN will join the Robert H. Lurie Comprehensive Cancer Center of Northwestern University as co-leader of the Translational Research in Solid Tumors Program and director of the Melanoma Program, effective May 1. He will also serve as director for faculty development at the Lurie Cancer Center.

Sosman comes from Vanderbilt-Ingram Cancer Center where he has an Ingram Chair for Cancer Research, directs the Melanoma Program and is co-leader of the Translational Research and Interventional Oncology Program. He is a recipient of the first Mary-Hendrickson Johnson American Cancer Society Melanoma Research Professorship.

The TRIST Program consists of accomplished faculty conducting translational studies centered on the themes of molecular and cell biology, early diagnosis, prognosis, risk factors, therapeutics and treatment of cancer of the aerodigestive tract, dermatologic, gastrointestinal, genitourinary and neuro-oncologic cancers.

Sosman has contributed to trials that led to the approval of at least eight new therapeutic agents for melanoma in the past five years. He continues to study new investigational agents to further increase treatment options for patients with melanoma, and is also recognized for his work with malignancies such as renal cell carcinoma.


ERIC DISHMAN was named director of the Precision Medicine Initiative Cohort Program at NIH.

Dishman will lead NIH’s effort to build the PMI longitudinal research study of one million or more volunteers. Dishman was a member of the working group that helped develop the design for the study.

Continue reading 42-15 Sosman Named Director of Melanoma Program at Northwestern University

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.